TGF beta 2 protein (Active) (ab629)
Our Abpromise guarantee covers the use of ab629 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||FuncS: Use at an assay dependent dilution.|
|SDS-PAGE||SDS-PAGE: Use at an assay dependent dilution.|
- BSC 1 cell growth inhibitorBSC-1 cell growth inhibitorBSC1 cell growth inhibitor
- CeterminG TSFG-TSFGlioblastoma derived T cell suppressorGlioblastoma derived T cell suppressor factorGlioblastoma-derived T-cell suppressor factorGTSFMGC116892MGFMilk growth factorPolyerginTGF B2TGF beta2TGF-beta-2TGF-beta2TGFB 2TGFB2TGFB2_HUMANTransforming growth factor beta 2Transforming growth factor beta-2
Defects in TGFB2 are the cause of Loeys-Dietz syndrome 4 (LDS4) [MIM:614816]. An aortic aneurysm syndrome with widespread systemic involvement. LDS4 is characterized by arterial tortuosity, aortic dissection, intracranial aneurysm and subarachnoid hemorrhage, hypertelorism, bifid uvula, pectus deformity, bicuspid aortic valve, arachnodactyly, scoliosis, foot deformities, dural ectasia, joint hyperflexibility, and thin skin with easy bruising and striae.
References for TGF beta 2 protein (Active) (ab629)
This product has been referenced in:
- Titeux M et al. Recessive dystrophic epidermolysis bullosa caused by COL7A1 hemizygosity and a missense mutation with complex effects on splicing. Hum Mutat 27:291-2 (2006). Read more (PubMed: 16470588) »